Kala Pharmaceuticals Inc (KALA.OQ)
16 Feb 2018
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|50||2017||Chairman of the Board, President, Chief Executive Officer|
|42||2017||Chief Financial Officer, Treasurer|
|47||2017||Chief Operating Officer|
|54||2017||Senior Vice President - Manufacturing and Supply Chain Management|
|47||2016||Senior Vice President - Regulatory Affairs and Quality Assurance|
- BRIEF-Orbimed Advisors Reports About 11 Pct Passive Stake In Kala Pharmaceuticals
- Future of Kala Pharma's dry eye drug uncertain after mixed results
- UPDATE 2-Future of Kala Pharma's dry eye drug uncertain after mixed results
- REFILE-Kala Pharma posts mixed results from dry eye disease drug studies
- BRIEF-Kala Pharmaceuticals Announces NDA For Inveltystm Accepted By U.S. FDA